Corcept Therapeutics Incorporated (CORT)

Short-term

Turnover ratios

The activity ratios for Corcept Therapeutics Incorporated reveal insights into the efficiency of the company's operations.

1. Inventory Turnover:
- Corcept's inventory turnover has improved steadily over the years from 0.26 in 2020 to 0.88 in 2024. This indicates that the company is selling its inventory more frequently, which can be a positive sign as it reduces the risk of obsolete inventory and can boost cash flow.

2. Receivables Turnover:
- The data provided does not show any figures for receivables turnover for any of the years. Receivables turnover ratio is crucial in analyzing how efficiently a company is collecting on its credit sales. In the absence of data, it is not possible to evaluate Corcept's efficiency in this aspect.

3. Payables Turnover:
- Similar to receivables turnover, the data does not provide any figures for payables turnover. Payables turnover ratio is essential for understanding how efficiently a company is managing its payments to suppliers. Without this information, it is challenging to assess Corcept's performance in this area.

4. Working Capital Turnover:
- Corcept's working capital turnover has shown a positive trend, increasing from 0.69 in 2020 to 2.04 in 2024. A higher working capital turnover ratio indicates that the company is utilizing its working capital more efficiently to generate sales revenue. This improvement suggests that Corcept is managing its working capital effectively over the years.

---

Average number of days

The analysis of Corcept Therapeutics Incorporated's activity ratios based on the provided data showcases trends in its Days of Inventory on Hand (DOH) over the years. The DOH represents the number of days a company holds its inventory before selling it. Corcept Therapeutics has seen a significant reduction in its DOH from 1,383.43 days in 2020 to 416.32 days in 2024. This indicates that the company has become more efficient in managing its inventory levels, potentially leading to cost savings and improved cash flow.

The Days of Sales Outstanding (DSO) and Number of Days of Payables data are not available, which limits the ability to conduct a comprehensive analysis of Corcept Therapeutics' overall working capital management efficiency. These ratios are essential for understanding how quickly the company collects payments from customers and pays its suppliers, respectively.

In conclusion, the decreasing trend in Corcept Therapeutics' Days of Inventory on Hand suggests a positive shift towards better inventory management and operational efficiency. However, further information on DSO and payables days is needed to provide a more holistic assessment of the company's overall activity ratios.

---

Long-term

The fixed asset turnover ratio for Corcept Therapeutics Incorporated has shown fluctuations over the years. It increased significantly from 2020 to 2021, indicating that the company was able to generate more revenue relative to its investment in fixed assets. However, it then decreased in 2022 before rebounding in 2023. The absence of data for 2024 makes it challenging to assess the trend in the most recent year.

In contrast, the total asset turnover ratio has generally shown an upward trend from 2020 to 2024. This suggests that the company has been more efficient in generating sales revenue relative to its total assets over this period. Despite some fluctuations, the overall improvement in total asset turnover indicates a positive trend in the company's ability to utilize its assets effectively to generate sales.

Overall, the fixed asset turnover and total asset turnover ratios reflect varying levels of efficiency in asset utilization over the years. The company's ability to manage its fixed assets and total assets efficiently plays a crucial role in determining its operational performance and overall financial health. Further analysis and consideration of other financial metrics would provide a more comprehensive understanding of Corcept Therapeutics' long-term activity ratios and financial performance.